Evoke Pharma, Inc.

NasdaqCM EVOK

Evoke Pharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -68.45%

Evoke Pharma, Inc. Operating Income Margin is -68.45% for the Trailing 12 Months (TTM) ending September 30, 2024, a 59.41% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Evoke Pharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -168.63%, a 54.15% change year over year.
Evoke Pharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -367.79%, a 46.56% change year over year.
Evoke Pharma, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -688.26%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: EVOK

Evoke Pharma, Inc.

CEO	Mr. Matthew J. D'Onofrio MBA
IPO Date	Sept. 25, 2013
Location	United States
Headquarters	420 Stevens Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Key trends

Past 5 years